ArticleJournal for immunotherapy of cancer2024
Correction: PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 <50%: a multiomics analysis.
PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.